What is HC Wainwright's Estimate for VERV FY2026 Earnings?

Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) - HC Wainwright issued their FY2026 earnings per share (EPS) estimates for Verve Therapeutics in a note issued to investors on Monday, May 19th. HC Wainwright analyst M. Kapoor forecasts that the company will post earnings per share of ($2.65) for the year. HC Wainwright has a "Buy" rating and a $25.00 price objective on the stock. The consensus estimate for Verve Therapeutics' current full-year earnings is ($2.49) per share.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.36. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. The business had revenue of $32.98 million for the quarter, compared to the consensus estimate of $7.13 million.

VERV has been the subject of a number of other reports. Cantor Fitzgerald raised Verve Therapeutics from a "neutral" rating to an "overweight" rating in a report on Tuesday, April 15th. Royal Bank of Canada cut their price target on Verve Therapeutics from $17.00 to $15.00 and set an "outperform" rating for the company in a report on Tuesday, March 4th. Guggenheim lifted their price target on Verve Therapeutics from $18.00 to $24.00 and gave the company a "buy" rating in a report on Tuesday, April 15th. William Blair reiterated an "outperform" rating on shares of Verve Therapeutics in a research report on Friday, February 21st. Finally, Canaccord Genuity Group lifted their price objective on Verve Therapeutics from $32.00 to $39.00 and gave the stock a "buy" rating in a research report on Tuesday, April 15th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $25.75.

Verve Therapeutics Stock Performance

Shares of NASDAQ VERV opened at $4.37 on Tuesday. The stock has a market cap of $389.55 million, a PE ratio of -1.78 and a beta of 1.82. The business has a fifty day moving average of $4.74 and a two-hundred day moving average of $5.85. Verve Therapeutics has a 52-week low of $2.86 and a 52-week high of $9.31.

Institutional Investors Weigh In On Verve Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Nisa Investment Advisors LLC raised its stake in Verve Therapeutics by 465.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 42,781 shares of the company's stock valued at $241,000 after acquiring an additional 35,214 shares during the period. Impact Partnership Wealth LLC bought a new position in Verve Therapeutics during the 4th quarter worth $70,000. China Universal Asset Management Co. Ltd. increased its position in Verve Therapeutics by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 17,952 shares of the company's stock worth $101,000 after buying an additional 1,676 shares during the period. Rhumbline Advisers increased its position in Verve Therapeutics by 1.9% during the 4th quarter. Rhumbline Advisers now owns 111,203 shares of the company's stock worth $627,000 after buying an additional 2,093 shares during the period. Finally, IFP Advisors Inc increased its position in Verve Therapeutics by 823,700.0% during the 4th quarter. IFP Advisors Inc now owns 8,238 shares of the company's stock worth $47,000 after buying an additional 8,237 shares during the period. Institutional investors own 97.11% of the company's stock.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.